Intralesional application of epidermal growth... (2016 study) Skip to main content
Review Acta orthopaedica et traumatologica turcica 2016

Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers.

Aktaş Ş, Baktıroğlu S, Demir L, Kılıçoğlu Ö, Topalan M, Güven E, et al., Acta orthopaedica et traumatologica turcica, 2016

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The researchers looked at 12 diabetic foot ulcers in 11 patients who were offered amputation as a last option, and gave each ulcer an injection of a growth factor medicine into the wound.

What They Found

In this small case series of 11 patients with advanced diabetic foot ulcers, 10 of 12 lesions healed completely after injection of epidermal growth factor (75 µg), and 2 patients had an amputation. The 11 patients (8 males, 3 females) had an average age of 62.2 years. Most had already had revascularization, hyperbaric oxygen therapy (HBOT) and negative pressure wound therapy, along with standard care, and their wounds had not healed. The 10 healed lesions were in 9 of the remaining patients. The authors concluded that the injection can prevent amputations in advanced ischemic cases, but they also noted that supporting evidence in the literature is lacking and that the treatment is costly.

What This Means for Canadian Patients

This study tested the growth factor injection, not HBOT. HBOT was one of the treatments most patients had already received without their wounds healing. The authors suggest the injection should be an option only after vascular evaluation (and intervention when possible), HBOT, negative pressure wound therapy and standard care have proven insufficient. With so few patients and no comparison group, these results do not show what HBOT itself did.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The study was small (11 patients), had no comparison group, and the abstract reports no statistical testing, so it cannot show that the injection caused the healing or separate its effect from the earlier treatments.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Review
Category Wound Care
Source Pubmed
PubMed ID 27130382
Year Published 2016
Journal Acta orthopaedica et traumatologica turcica
MeSH Terms Aged; Amputation, Surgical; Diabetic Foot; Epidermal Growth Factor; Female; Humans; Hyperbaric Oxygenation; Injections, Intralesional; Male; Middle Aged; Negative-Pressure Wound Therapy; Recombinant Proteins; Turkey; Wound Healing

Cite This Study

Share

This study relates to Problem Wounds. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Wound Care

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 1, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology